Ana Ortiz-Guerrero, MD
Nephrology · Torrance, CANPI 1275776536
Payments from drug & device makers
Across 641 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Vifor Pharma, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- AstraZeneca$918
- Travere Therapeutics, Inc.$911
- Novo Nordisk$833
- plus $6K from 27 others
What the payments were for
- Food & beverage$11,830100%
- Education$400%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 59 | $1,152 |
| Vifor Pharma, Inc. | 57 | $1,069 |
| Otsuka America Pharmaceutical, Inc. | 47 | $1,010 |
| AstraZeneca(2 entities) | 45 | $918 |
| Travere Therapeutics, Inc. | 75 | $911 |
| Novo Nordisk | 49 | $833 |
| Akebia Therapeutics Inc | 42 | $732 |
| Bayer | 38 | $719 |
| Calliditas Therapeutics US Inc. | 32 | $629 |
| Mallinckrodt Hospital Products Inc. | 28 | $616 |
| OPKO Pharmaceuticals, LLC | 30 | $531 |
| Fresenius USA Marketing, Inc. | 27 | $491 |
| Ardelyx, Inc. | 19 | $341 |
| Novartis | 20 | $331 |
| Boehringer Ingelheim | 14 | $308 |
| Aurinia Pharma U.S., Inc. | 11 | $268 |
| Sanofi | 8 | $150 |
| ANI Pharmaceuticals, Inc. | 7 | $141 |
| Johnson & Johnson | 6 | $135 |
| GSK | 6 | $123 |
| Kyowa Kirin, Inc. | 3 | $77 |
| Arbor Pharmaceuticals, Inc. | 4 | $65 |
| Scpharmaceuticals Inc. | 2 | $50 |
| Apellis Pharmaceuticals, Inc. | 2 | $49 |
| Ultragenyx Pharmaceutical Inc. | 2 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $40 |
| Genentech USA, Inc. | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Alvogen Inc | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$11,871 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProcritEpoetin Alfa | 94 | $63,432 |
| FarxigaDapagliflozin Propanediol | 61 | $54,604 |
| OzempicSemaglutide | 40 | $48,790 |
| LokelmaSodium Zirconium Cyclosilicate | 33 | $35,966 |
| VelphoroSucroferric Oxyhydroxide | 11 | $32,829 |
| EliquisApixaban | 22 | $25,753 |
| JanuviaSitagliptin Phosphate | 15 | $22,644 |
| LinzessLinaclotide | 22 | $17,804 |
| Sevelamer Carbonate | 68 | $15,629 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $13,938 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 53 | $12,578 |
| RetacritEpoetin Alfa-Epbx | 28 | $12,488 |
| Cinacalcet Hcl | 18 | $9,707 |
| TradjentaLinagliptin | 15 | $9,696 |
| Nifedipine ErNifedipine | 210 | $7,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $918 | $90,57094 claims |
| Johnson & JohnsonProcrit | $135 | $63,43294 claims |
| Novo NordiskOzempic | $833 | $48,79040 claims |
| Fresenius USA Marketing, Inc.Velphoro | $491 | $32,82911 claims |
| Boehringer IngelheimTradjenta | $308 | $9,69615 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $65 | $3,11714 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $141 | $2,455160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.
Other nephrology in Torrance
- Sharon AdlerTorrance$650K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.